Breaking News
February 25, 2018 - New staining method helps analyze 3D tissue samples using Nano-CT system
February 25, 2018 - Rare immune cell may prove to be potent weapon in fighting against cancer
February 25, 2018 - Connection between heart disease and cancer treatment
February 25, 2018 - Longer Endocrine Tx Better in Prostate Cancer
February 25, 2018 - Gene therapy restores normal blood glucose levels in mice with type 1 diabetes
February 25, 2018 - Desymmetrization paves way for new bioactive compounds
February 25, 2018 - Study finds underutilization of less expensive, post-acute care options for older adults
February 25, 2018 - UNIST researchers introduce new biosensing contact lens for diabetics
February 25, 2018 - Research consortium develops first 3D computer model of metabolic processes
February 25, 2018 - Adding hope to health messages may help promote preventative actions, researchers say
February 25, 2018 - Sudden Hearing Loss Recovery Hampered by Metabolic Syndrome
February 25, 2018 - First human trial of potentially game-changing diabetes treatment set to commence
February 25, 2018 - Child’s snacking patterns could be linked to genetics, study finds
February 25, 2018 - Patients with terminal cancer may be less competent to make big decisions
February 25, 2018 - Study highlights risks involved in short-term use of PICCs
February 25, 2018 - Study shows no increase in complications with ‘ad lib’ oral intake during labor
February 25, 2018 - Although Plaquenil (Hydroxychloroquine) Eases Rheumatoid Arthritis Pain it Won’t Help ‘Regular’ Arthritis
February 25, 2018 - Methotrexate May Help in Chronic Viral Arthritis
February 25, 2018 - Lack of guidance may delay a child’s first trip to the dentist
February 25, 2018 - Study shows cost-effectiveness of screening for fracture risk in older postmenopausal women
February 24, 2018 - Younger women with SCAD may benefit most from conservative treatment
February 24, 2018 - Blood Test for Concussion OK’d
February 24, 2018 - What are symptoms of an alcohol use disorder? – Rethinking Drinking
February 24, 2018 - Streamlined, cost-cutting post-treatment dental advice via iPad
February 24, 2018 - Researchers discover new regulator of the immune system
February 24, 2018 - Reducing red tape for traveling nurses
February 24, 2018 - Study supports benefits of meditation in control of attention and emotions
February 24, 2018 - Flu Vax Data ‘Only Tell Half the Story’
February 24, 2018 - Calculators – Rethinking Drinking – NIAAA
February 24, 2018 - From stem cells to a functional heart—the role of the Mesp1 gene
February 24, 2018 - Non-adherence to sleep apnea treatment linked to increased hospital readmissions
February 24, 2018 - Exercise-related posts influence health of social media pals
February 24, 2018 - Will Device Meetings in Europe Suffer Under New Ethics Rule?
February 24, 2018 - Nonstatin drug use increases by 124% in U.S., related expenditures triple
February 24, 2018 - Annual foot screening could help spot heart irregularities in people with diabetes
February 24, 2018 - Researchers developing rapid saliva test to detect Zika virus
February 24, 2018 - For Older Men, Even Light Exercise Helps
February 24, 2018 - Healthy Strategies to Beat Stress
February 24, 2018 - Cancer killing clue could lead to safer and more powerful immunotherapies
February 24, 2018 - Repeated sick days do not affect children’s learning ability, study shows
February 24, 2018 - New two-child policy in China could negatively affect women’s status and gender equality
February 24, 2018 - New research project to determine why mine dust-related lung diseases are on the rise
February 24, 2018 - A Tribute to Dr. Ray Lipicky: The Man Who Transformed Cardiology
February 24, 2018 - ClinicalTrials.gov: Child, Foster
February 24, 2018 - Study shows age doesn’t affect survival in patients with non-Hodgkin lymphoma after HCT
February 24, 2018 - Researchers explore how evolutionary processes guide pathways of cells
February 24, 2018 - Discovery may result in new medication to build stronger muscles in old age
February 24, 2018 - New study identifies possible target for treatment of dangerous allergic reactions
February 24, 2018 - Targeted vaccination can be successful in containing epidemic outbreaks
February 24, 2018 - Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of Medicine
February 24, 2018 - ‘The Best Deals of Any Payer’: What We Heard This Week
February 24, 2018 - Blood and urine tests developed to indicate autism in children
February 24, 2018 - New low-cost microfluidic device brings single-cell technology to bedside
February 24, 2018 - Covestro and Pittsburgh Penguins announce multi-year unique partnership
February 24, 2018 - Children from low-income areas have poor outcomes after heart surgery, study finds
February 24, 2018 - Some genes can drive both metastasis and initial stages of tumor growth
February 24, 2018 - Visaris Americas announces installation of fully robotic Vision C digital X-ray suite at OGHS
February 24, 2018 - New discovery could accelerate clinical translation of stem cell-based therapies
February 24, 2018 - Respiratory disease patients with arthritis struggle to use complex inhalers
February 24, 2018 - FDA Alert: Labetalol Hydrochloride Injection by Hospira: Recall
February 24, 2018 - Flu, Tdap Vax Safe for Babies 6 Months Later
February 24, 2018 - Adults with autism show a diminished brain response to hearing their own name
February 24, 2018 - Study provides insight into neurobiology of dying
February 24, 2018 - Study finds tobacco smoke exposure among most adolescents in economically disadvantaged population
February 24, 2018 - U.S. clinical sites evaluating antibody-based therapies to prevent two common bacterial infections
February 24, 2018 - UCLA researchers use fluorescent colored proteins to trace origin of heart cells
February 24, 2018 - UC Riverside researchers discover way to halt cancer metastasis
February 24, 2018 - Home Routines Can Boost a Child’s Readiness for School
February 24, 2018 - FDA Investigating Misuse, Abuse of Gabapentinoids
February 24, 2018 - Scientists find key proteins control risk of osteoarthritis during aging
February 24, 2018 - Izon announce the launch of the qEV2 and qEV10 Exosome Isolation columns
February 24, 2018 - New CSIRO technology can create clean drinking water
February 24, 2018 - Treating sleep-disordered breathing may improve prognosis of heart failure patients
February 24, 2018 - More boys begin school a year late than girls, study finds
February 24, 2018 - Early life exposure to green space could have beneficial effects on cognitive function
February 24, 2018 - Joint Surgery: Aspirin Equals NOAC for Post-Acute VTE Prevention
February 23, 2018 - Scientists identify new marker of arthritis in mice
February 23, 2018 - Beetroot juice supplements may benefit patients with heart failure
February 23, 2018 - New study identifies novel molecular biomarkers of preeclampsia
February 23, 2018 - Researchers discover new link between gut bacteria and obesity
Aeterna Zentaris Announces FDA Approval of Macrilen (macimorelin) for Diagnosis of Adult Growth Hormone Deficiency

Aeterna Zentaris Announces FDA Approval of Macrilen (macimorelin) for Diagnosis of Adult Growth Hormone Deficiency

image_pdfDownload PDFimage_print

Aeterna Zentaris Announces FDA Approval of Macrilen (macimorelin) for Diagnosis of Adult Growth Hormone Deficiency

CHARLESTON, S.C. December 20, 2017 — Aeterna Zentaris Inc. (NASDAQ and TSX: AEZS), a specialty biopharmaceutical company engaged in developing and commercializing pharmaceutical therapies, announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Macrilen (macimorelin), an orally available ghrelin agonist, to be used in the diagnosis of patients with adult growth hormone deficiency (AGHD). The Company estimates that approximately 60,000 tests for suspected AGHD are being conducted each year across the United States, Canada and Europe.

“Aeterna Zentaris is proud of our commitment to patients with suspected AGHD and to the endocrinology community who we are confident will welcome an easier safe and effective oral diagnostic tool,” said Michael V. Ward, Chief Executive Officer, Aeterna Zentaris. “In the absence of an FDA-approved diagnostic test for AGHD, Macrilen fills an important gap and addresses a medical need for a convenient test that will better serve patients and health providers.”

Macrilen (macimorelin) stimulates the secretion of growth hormone from the pituitary gland into the circulatory system. Stimulated growth hormone levels are measured in four blood samples over ninety minutes after oral administration of Macrilen (macimorelin) for the assessment of growth hormone deficiency (“GHD”). Prior to the approval of Macrilen (macimorelin), the historical gold standard for evaluation of AGHD was the insulin tolerance test (“ITT”), an intravenous test requiring many blood draws over several hours. The ITT procedure is inconvenient for patients and medical practitioners and may contraindicate in patients, such as those with coronary heart disease or seizure disorder, because it requires the patient to experience hypoglycemia to obtain an accurate result.

“Clinical studies have demonstrated that growth hormone stimulation testing for AGHD with oral Macrilen (macimorelin) is reliable, well-tolerated, reproducible, safe and a much simpler test to conduct than currently available options,” said Kevin Yuen, MD, clinical investigator and neuroendocrinologist, Barrow Neurological Institute, and medical director of the Barrow Neuroendocrinology Clinic, Phoenix, Arizona. “The availability of Macrilen (macimorelin) will greatly relieve the burden of endocrinologists in reliably and accurately diagnosing AGHD.”

Aeterna Zentaris intends to make Macrilen (macimorelin) available commercially in the United States during the first quarter of 2018.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on developing and commercializing Macrilen™ (macimorelin). On November 27, 2017 Aeterna Zentaris announced that the Marketing Authorization Application (MAA) for the use of Macrilen™ (macimorelin) for the evaluation of AGHD was accepted by the European Medicines Agency (EMA) for regulatory review. For more information, visit www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe-harbor provisions of the U.S. Securities Litigation Reform Act of 1995 and applicable Canadian securities laws, which reflect our current expectations regarding future events. Forward-looking statements may include, but are not limited to statements preceded by, followed by, or that include the words “expects,” “believes,” “intends,” “would,” “could,” “may,” “anticipates,” and similar terms that relate to future events, performance, or our results. Forward-looking statements involve known risks and uncertainties, many of which are discussed under the caption “Key Information – Risk Factors” in our most recent Annual Report on Form 20-F filed with the relevant Canadian securities regulatory authorities in lieu of an annual information form and with the U.S. Securities and Exchange Commission (“SEC”). Such statements include, but are not limited to, statements about the timing of, and prospects for, regulatory approval and commercialization of our product candidates, statements about the status of our efforts to establish a commercial operation and to obtain the right to promote or sell products that we did not develop and estimates regarding our capital requirements and our needs for, and our ability to obtain, additional financing. Known and unknown risks and uncertainties could cause our actual results to differ materially from those in forward-looking statements. Such risks and uncertainties include, among others, our now heavy dependence on the success of Macrilen™ (macimorelin) and the continued availability of funds and resources to successfully launch the product, and, more generally, uncertainties related to the regulatory process, the rejection of the MMA by the EMA and the ability of the Company to efficiently commercialize Macrilen™ (macimorelin), the degree of market acceptance of Macrilen™ (macimorelin), our ability to obtain necessary approvals from the relevant regulatory authorities to enable us to use the desired brand names for our products, the impact of securities class action litigation, the litigation involving two former officers of the Company, or other litigation, on our cash flow, results of operations and financial position; any evaluation of potential strategic alternatives to maximize potential future growth and stakeholder value may not result in any such alternative being pursued, and even if pursued, may not result in the anticipated benefits, our ability to take advantage of business opportunities in the pharmaceutical industry, our ability to protect our intellectual property, the potential of liability arising from shareholder lawsuits and general changes in economic conditions. Investors should consult the Company’s quarterly and annual filings with the applicable Canadian securities regulators and the SEC for additional information on risks and uncertainties. Given these uncertainties and risk factors, readers are cautioned not to place undue reliance on these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law.

Source: Aeterna Zentaris Inc.

Posted: December 2017

Related Articles:

  • NDA for Macrilen for the Evaluation of Growth Hormone Deficiency in Adults Granted December 30, 2017 PDUFA Date – July 18, 2017
  • Aeterna Zentaris Resubmits NDA for Macrilen for the Evaluation of Growth Hormone Deficiency in Adults – June 30, 2017
  • Aeterna Zentaris Intends to File NDA with Respect to Macrilen in Third Quarter of 2017 – March 30, 2017
  • Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen – February 13, 2017
  • Aeterna Zentaris Completes Patient Recruitment for Confirmatory Phase 3 Trial of Macrilen – October 26, 2016
  • Aeterna Zentaris Announces Plans to Initiate Phase 3 Study of Macrilen in AGHD – April 13, 2015
  • FDA Issues Complete Response Letter for Macrilen (macimorelin) NDA in Adult Growth Hormone Deficiency – November 6, 2014
  • Aeterna Zentaris NDA for Macimorelin Acetate in AGHD Accepted for Filing by the FDA – January 6, 2014
  • Aeterna Zentaris Submits New Drug Application to FDA for Macimorelin Acetate (AEZS-130) for Evaluation of AGHD – November 5, 2013

Macrilen (macimorelin) FDA Approval History

Tagged with:

About author

Related Articles